Resolution on patenting BRCA1 and BRCA2 (breast cancer) genes

This procedure addresses the ethical and legal concerns regarding the patenting of the BRCA1 and BRCA2 genes, which are linked to an increased risk of breast and ovarian cancer. It examines whether genetic sequences should be treated as industrial inventions or as common human heritage that should remain accessible for medical research.

This affects biotechnology companies, medical researchers, and patients. It seeks to ensure that patents do not restrict access to essential genetic testing or hinder the development of life-saving diagnostic tools.